{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:23:59Z","timestamp":1787862239100,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40122-024-00616-3","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T08:15:06Z","timestamp":1720080906000},"page":"1151-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase\u00a03 Study by Stroke Type and Location"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03901352","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Koichi","family":"Hosomi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunika","family":"Kikumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kuroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"616_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/17474930211065917","volume":"17","author":"VL Feigin","year":"2022","unstructured":"Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global stroke fact sheet 2022. Int J Stroke. 2022;17:18\u201329.","journal-title":"Int J Stroke"},{"key":"616_CR2","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2017\/e418","volume":"73","author":"MJM Ramos-Lima","year":"2018","unstructured":"Ramos-Lima MJM, Brasileiro IC, Lima TL, Braga-Neto P. Quality of life after stroke: impact of clinical and sociodemographic factors. Clinics (Sao Paulo). 2018;73:e418.","journal-title":"Clinics (Sao Paulo)"},{"key":"616_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.25122\/jml-2021-0361","volume":"14","author":"S Strilciuc","year":"2021","unstructured":"Strilciuc S, Grad DA, Radu C, et al. The economic burden of stroke: a systematic review of cost of illness studies. J Med Life. 2021;14:606\u201319.","journal-title":"J Med Life"},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ijs.12325","volume":"9","author":"NE Andrew","year":"2014","unstructured":"Andrew NE, Kilkenny M, Naylor R, et al. Understanding long-term unmet needs in Australian survivors of stroke. Int J Stroke. 2014;9:106\u201312.","journal-title":"Int J Stroke"},{"key":"616_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.758536","volume":"12","author":"KT Kim","year":"2021","unstructured":"Kim KT, Chang WK, Jung YS, et al. Unmet needs for rehabilitative management in common health-related problems negatively impact the quality of life of community-dwelling stroke survivors. Front Neurol. 2021;12:758536.","journal-title":"Front Neurol"},{"key":"616_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028137","volume":"9","author":"T Chen","year":"2019","unstructured":"Chen T, Zhang B, Deng Y, Fan JC, Zhang L, Song F. Long-term unmet needs after stroke: systematic review of evidence from survey studies. BMJ Open. 2019;9:e028137.","journal-title":"BMJ Open"},{"key":"616_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JPR.S375063","volume":"16","author":"F Xiong","year":"2023","unstructured":"Xiong F, Shen P, Li Z, et al. Bibliometric analysis of post-stroke pain research published from 2012 to 2021. J Pain Res. 2023;16:1\u201320.","journal-title":"J Pain Res"},{"key":"616_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S1474-4422(09)70176-0","volume":"8","author":"H Klit","year":"2009","unstructured":"Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol. 2009;8:857\u201368.","journal-title":"Lancet Neurol"},{"key":"616_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.mayocp.2016.01.017","volume":"91","author":"JC Watson","year":"2016","unstructured":"Watson JC, Sandroni P. Central neuropathic pain syndromes. Mayo Clin Proc. 2016;91:372\u201385.","journal-title":"Mayo Clin Proc"},{"key":"616_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrneurol.2015.58","volume":"11","author":"K Hosomi","year":"2015","unstructured":"Hosomi K, Seymour B, Saitoh Y. Modulating the pain network\u2013neurostimulation for central poststroke pain. Nat Rev Neurol. 2015;11:290\u20139.","journal-title":"Nat Rev Neurol"},{"key":"616_CR11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/STROKEAHA.111.671008","volume":"44","author":"MJ O\u2019Donnell","year":"2013","unstructured":"O\u2019Donnell MJ, Diener HC, Sacco RL, Panju AA, Vinisko R, Yusuf S. Chronic pain syndromes after ischemic stroke: PRoFESS trial. Stroke. 2013;44:1238\u201343.","journal-title":"Stroke"},{"key":"616_CR12","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1007\/s12325-020-01388-w","volume":"37","author":"A Liampas","year":"2020","unstructured":"Liampas A, Velidakis N, Georgiou T, et al. Prevalence and management challenges in central post-stroke neuropathic pain: a systematic review and meta-analysis. Adv Ther. 2020;37:3278\u201391.","journal-title":"Adv Ther"},{"key":"616_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113.","journal-title":"Eur J Neurol"},{"key":"616_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162\u201373.","journal-title":"Lancet Neurol"},{"key":"616_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4103\/neuroindia.NI_45_16","volume":"65","author":"J Kalita","year":"2017","unstructured":"Kalita J, Chandra S, Misra UK. Pregabalin and lamotrigine in central poststroke pain: a pilot study. Neurol India. 2017;65:506\u201311.","journal-title":"Neurol India"},{"key":"616_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/JPR.S63028","volume":"7","author":"K Onouchi","year":"2014","unstructured":"Onouchi K, Koga H, Yokoyama K, Yoshiyama T. An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. J Pain Res. 2014;7:439\u201347.","journal-title":"J Pain Res"},{"key":"616_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.pain.2010.12.023","volume":"152","author":"JS Kim","year":"2011","unstructured":"Kim JS, Bashford G, Murphy TK, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain. 2011;152:1018\u201323.","journal-title":"Pain"},{"issue":"18","key":"616_CR18","first-page":"3511385","volume":"2022","author":"Z Bo","year":"2022","unstructured":"Bo Z, Jian Y, Yan L, et al. Pharmacotherapies for Central Post-Stroke Pain: a systematic review and network meta-analysis. Oxid Med Cell Longev. 2022;2022(18):3511385.","journal-title":"Oxid Med Cell Longev"},{"key":"616_CR19","unstructured":"Mirogabalin besylate (Tarlige\u24c7) tablets [package insert, version 7]. Daichii-Sankyo Co., Ltd.; Tokyo, Japan: 2023. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00070625.pdf. [In Japanese]. Accessed 13 Mar 2024."},{"key":"616_CR20","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1212\/WNL.0000000000201709","volume":"100","author":"T Ushida","year":"2023","unstructured":"Ushida T, Katayama Y, Hiasa Y, et al. Mirogabalin for central neuropathic pain after spinal cord injury: a randomized, double-blind, placebo-controlled, phase\u00a03 study in Asia. Neurology. 2023;100:e1193\u2013206.","journal-title":"Neurology"},{"key":"616_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40122-023-00513-1","volume":"12","author":"T Ushida","year":"2023","unstructured":"Ushida T, Katayama Y, Hiasa Y, et al. Long-term safety and efficacy of mirogabalin for central neuropathic pain: a multinational, phase\u00a03, 52-week, open-label study in Asia. Pain Ther. 2023;12:963\u201378.","journal-title":"Pain Ther"},{"key":"616_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","volume":"30","author":"R Melzack","year":"1987","unstructured":"Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191\u20137.","journal-title":"Pain"},{"key":"616_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pain.2007.06.033","volume":"136","author":"JH Vranken","year":"2008","unstructured":"Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150\u20137.","journal-title":"Pain"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:48:36Z","timestamp":1726145316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00616-3","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"19 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koichi Hosomi received lecture fees, consulting fees, and contract research funds from Daiichi Sankyo Co., Ltd., lecture fees outside the submitted work from Medtronic Japan Co., Ltd., Boston Scientific Japan K.K., and Nippon Zoki Pharmaceutical Co., Ltd., consulting fees outside the submitted work from Teijin Pharma Ltd., Araya Inc., and the Japanese Society of Psychiatry and Neurology, travel expenses outside the submitted work from Integra Japan Co., Ltd., and grants outside the submitted work from the Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, and Taiju Life Social Welfare Foundation. Takahiro Ushida received lecture fees and scholarship fees from Daiichi Sankyo Co., Ltd., and lecture fees outside the submitted work from Asahi Kasei Pharma Corp., AbbVie G.K., Viatris Inc., Eisai Co., Ltd., Suzuken Co., Ltd., Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Nipro Corp., Eli Lilly Japan K.K., Nippon Zoki Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Pfizer Japan Inc., Boston Scientific Japan K.K., Mundipharma K.K., Medical QOL Co., Ltd., Janssen Pharmaceutical K.K., Tsumura & Co., Taisho Toyama Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corp. The institution to which Takahiro Ushida\u00a0is affiliated (Aichi Medical University) received research funding outside the submitted work from Nippon Zoki Pharmaceutical Co., Ltd., Kyoto University, Pascal Universe Co., Ltd., and BonBon Inc., and scholarship fees outside the submitted work from Astellas Pharma Inc., AbbVie G.K., Osuga Clinic, Zenki Clinic, Clinics of Youteikai, Kowa Medical Society, Otsuka Pharmaceutical Co., Ltd., Tsumura & Co., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nipro Corp., Eli Lilly Japan K.K., Pfizer Japan Inc., Boston Scientific Japan K.K., and Mochida Pharmaceutical Co., Ltd. Yoichi Katayama has no conflicts of interest to declare. Hiroshi Sakoda, Kunika Kikumori, and Masanori Kuroha are employees of Daiichi Sankyo Co., Ltd., which funded this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the ethical principles that have their origins in the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and the Japanese Ministry of Health, Labour and Welfare. The study protocol, protocol amendments, informed consent forms, and information sheets were approved by the relevant independent ethics committees or institutional review boards at each study center [], and all patients provided written informed consent prior to participating in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}